Articles tagged with Vaccine Development
Regenerative medicine holds promise for affordable treatments and offsetting donor shortages, particularly for diabetes, heart disease, and infectious diseases. The study prioritizes 10 applications, including novel insulin replacement methods, regenerating failed heart muscle, and engineered immune cells.
Despite an increase in drug development for killer diseases, researchers argue that more incentives and access guarantees are needed to address the lack of economic demand. The rise of public-private partnerships (PPPs) is also cited as a contributing factor.
The study found a significant decrease in the age-adjusted HSV-2 seroprevalence from 17.0% in 1999-2004 to 21.0% in 1988-1994, with decreases especially concentrated among persons aged 14 to 19 years. The prevalence of genital herpes caused by HSV-1 may be increasing.
The International AIDS Vaccine Initiative proposes new scientific and policy initiatives to accelerate AIDS vaccine development, fostering capacity building in developing countries. The Blueprint highlights the need for a dynamic global research and development program with clear spending targets and equitable financial burden-sharing.
A Kenyan study confirms that routine Hib vaccination significantly reduced invasive Hib disease to 88% below baseline. This finding suggests that virtual elimination of the devastating disease is possible if more countries adopt the vaccine as part of their national immunization programs.
A new study outlines an innovative approach to create a CMV vaccine using recombinant technologies. Researchers have successfully introduced human CMV genes into mouse CMV, resulting in a novel form of the virus that can trigger an immune response without sustaining infection.
J-P Garnier, GSK CEO, emphasizes the company's commitment to providing affordable HIV drugs and vaccines for diseases affecting the developing world. He highlights GSK's efforts to introduce modern HIV drugs at lower prices and protect innovation through patents.
Sharon Witonsky, a clinician and researcher at Virginia Tech, has received the Pfizer Award for her work on EPM, a neurologic disease that affects horses. Her research aims to discover the mechanism of Sarcocystis neurona's effects on horses and develop more effective diagnostic tests and vaccines.
The introduction of Gardasil in the USA is proving problematic due to social and cultural resistance. The Bill and Melinda Gates Foundation has donated $27.7 million to PATH to research introducing the vaccine in developing countries, where Merck and GSK can assist by identifying cultural barriers.
A new H5N1 vaccine has demonstrated cross-protection in ferrets against different variants of the virus, offering a promising solution for stockpiling in the event of a human outbreak. The vaccine was shown to completely protect ferrets from infection and reduce viral multiplication.
Dental caries is a widespread and increasing problem globally, with 5 billion people affected. Forsyth researchers aim to develop a vaccine targeting bacterial accumulation on teeth, with initial focus on mucosal vaccines for young children.
Routine childhood pneumococcal vaccination has the potential to save millions of lives, particularly children under five years old. The seven-valent vaccine is already licensed and in use in over 60 countries, and formulations with additional serotypes are being developed to target strains commonly causing death and disability.
A new potential vaccine against deadly leishmaniasis has been developed by a research group led by Peter H. Seeberger, combining a virosome delivery system with a synthetic carbohydrate antigen. This innovative approach aims to overcome the limitations of existing vaccines and provide a strong protective action against the disease.
Researchers identify matrix protein as critical component in VSV's ability to invade cells and replicate, leading to potential vaccine development and anti-viral agents. The discovery also provides insights into how viruses shut down cell protein-making capabilities.
Researchers at Rice University propose a novel approach to combat Dengue virus by administering multiple vaccines simultaneously at different locations on the body, bypassing immunodominance and enhancing immunity against all four closely related viruses. This strategy has implications for other diseases such as HIV and cancer.
Researchers analyzed data from nearly 63,000 patients hospitalized for pneumonia between 1999 and 2003. Vaccination was associated with a 40-70% lower risk of death during hospitalization compared to unvaccinated or unknown status patients.
Researchers sequenced and analyzed over 1.8 million genetic codes to determine functions of genes involved in polysaccharide capsule production. The new vaccine protects children from many common serotypes, but monitoring is needed to track potential changes in capsular types.
The University of Pittsburgh has established an Immune Modeling Center to study immune responses to infectious diseases using mathematical modeling. The center will focus on understanding innate and adaptive immune responses to influenza A virus, Mycobacterium tuberculosis, and Francisella tularensis.
The Biodesign Institute is developing a subunit vaccine against tularemia using unique technologies, including high-throughput gene building and gene expression measurement. This approach aims to produce an effective and safe vaccine by identifying the best pathogen components to elicit an immune response.
Researchers found that identical twins infected with the same HIV strain had different T-cell receptor characteristics, indicating a random and unpredictable immune response. This discovery challenges the idea of developing a single, universal vaccine for everyone.
The RTS,S/AS02A vaccine reduced clinical malaria episodes by 35% and severe malaria episodes by 49%. The study followed 14,442 children who received a three-dose regimen of the vaccine in 2003 for an 18-month follow-up period.
Pall Corporation's total process management approach can improve vaccine production economics by reducing time, safety risks, and expenses. The use of scalable and disposable technologies enables efficient processing of larger volumes, addressing the need for increased manufacturing capacity in response to pandemic threats.
Researchers outline new approaches to help developing countries address neglected diseases by pooling resources through health innovation networks. The recommended approach emphasizes harmonized development in six sectors, including manufacturing, research and development, and intellectual property systems.
Researchers reconstructed the 1918 flu virus using reverse genetics, a technique developed by Mount Sinai School of Medicine researchers. The study reveals that the virus is extremely virulent in mice and grows rapidly in human lung cells.
The National Institute of Allergy and Infectious Diseases has awarded $60 million to support the development of new tularemia vaccines. This contract is part of a larger NIAID biodefense awards package, which includes funding for Regional Biocontainment Laboratories and research on high-priority pathogens such as anthrax and smallpox.
Robert Gallo emphasizes the need for a rational approach to HIV vaccine development, ignoring empirically driven methods and focusing on solid knowledge of HIV biology. He suggests leveraging the Gates's Foundation's Grand Challenge for Global Health to find practical solutions to scientific roadblocks.
A report on vaccine markets is criticized for favoring large firms and delaying access to effective vaccines. The author recommends using advanced purchase commitments as a complement to research funding.
Researchers find B-1a cells regulate innate immunity, while B-1b cells drive adaptive long-term response to infections. The discovery sheds light on vaccine action and potential insights into designing vaccines.
A U of T study identified barriers to future HIV vaccine acceptance, including concerns about power dynamics, affordability, and stigma. Researchers found that women viewed vaccination as empowering and a way to protect themselves and their children.
CHAVI will focus on solving key questions about HIV interactions with the body and designing improved vaccines. The center will also evaluate promising candidates in small-scale clinical trials.
Scientists have sequenced the genomes of three parasites responsible for sleeping sickness, Chagas disease, and leishmaniasis, providing critical information for drug and vaccine development. The research identified core genes that could serve as targets for effective drugs against all three parasites.
The NIAID-funded CHAVI center will focus on understanding early stages of HIV infection, developing new research tools, and designing improved HIV vaccines. The center aims to accelerate the development of a safe and effective preventive vaccine for HIV/AIDS through collaborative research.
Researchers are developing genetically altered malaria parasites to stimulate immunity against the disease. The goal is to boost the immune system in a similar way to how the altered polio bacteria triggers immunity against polio.
A new study estimates that dengue fever costs over $13 million annually, equivalent to 940,000 lost workdays of output. A potential vaccine could offset 87% of treatment costs, reducing the economic burden on governments and households.
The Yale project aims to create a predictive model system for vaccine testing, addressing the need to predict vaccine safety and effectiveness. The team will study a novel solution using mice engineered with human immune systems, generated with technology developed in Switzerland.
A study found that routine immunisation of infants with the Haemophilus influenzae type b (Hib) vaccine significantly reduced meningitis incidence rates in The Gambia. The researchers hope their findings will encourage other developing countries to adopt Hib vaccination programmes, helping achieve the United Nations' goal of decreasing...
The project aims to formulate a vaccine with a safe, low-cost additive derived from weakened Salmonella bacteria, which can enhance the immune response. A single-dose oral vaccine is also being developed, making it more accessible and practical for use in developing countries.
Researchers have developed a new vaccine that is 100 percent effective in protecting monkeys from infection with deadly viruses Ebola and Marburg. The vaccine targets dendritic cells, which are the same cells attacked by these viruses.
Dr. Albert Z. Kapikian receives the Sabin Gold Medal for developing the first licensed rotavirus vaccine, saving millions of lives worldwide. His pioneering work in electron microscopy and virus characterization has been widely recognized by NIAID Director Anthony Fauci and H.R. Shepherd.
The US vaccine system is fragile and needs significant improvements, the authors report. Despite record low levels of vaccine-preventable diseases and high immunization rates among children, supply chain issues, cost concerns, and safety threats threaten to derail progress.
NIAID has awarded $27 million to institutions and companies to develop medical countermeasures against Category A bioterror agents, including botulinum toxin and Ebola. The awards will support the development of new treatments and therapies using promising scientific discoveries.
Aeras and UCLA announce a license deal for rBCG30, a live recombinant vaccine technology developed at UCLA's David Geffen School of Medicine. The vaccine has shown promising results in initial clinical studies and holds potential to reduce TB disease burden globally.
Researchers at Yale University have identified a molecule that detects parasitic infections in humans, shedding light on how the body recognizes parasites. The discovery of Toxoplasma profilin and TLR11 provides crucial information for developing novel strategies to combat parasitic infections.
A four-year study published in the New England Journal of Medicine confirms RSV as a substantial burden of disease in adults, similar to influenza A. The study calls for the development of an RSV vaccine for elderly and high-risk adults.
Using informatics and computer modelling, researchers can speed up vaccine development by identifying common patterns in 'foreign' protein sequences. This approach has the potential to significantly reduce the number of proteins that need to be experimentally tested.
A new influenza vaccine developed using insect cells can produce a strong immune response in humans and may be scaled up for commercial manufacture. This rapid method uses a purified concentration of hemagglutinin to elicit an immune response against specific flu strains.
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting applications for Clinical Trials Units to lead in the development and evaluation of treatments, prevention strategies, and vaccines for HIV/AIDS. The selected units will focus on interventions that can be employed in resource-limited settings.
Researchers at UCI create a new method to rapidly discover antigens for vaccines, enabling the expression of hundreds of proteins in just one week. This technique addresses the bottleneck in processing large amounts of data from genome sequences, allowing for faster vaccine development and improved safety.
The Global HIV/AIDS Vaccine Enterprise has launched a scientific strategic plan to address major roadblocks in HIV vaccine development and proposes an innovative collaborative model for researchers worldwide. The plan aims to harness new opportunities, including an expanded pipeline of HIV vaccine candidates and improved animal models.
A vaccine against cervical cancer has been developed by Dutch researcher Laura Bungener. The vaccine induces an immune response to proteins from human papillomavirus (HPV), rendering it harmless and preventing the growth of tumors. Laboratory animals with existing tumors could also be treated with this vaccination.
The NIAID human clinical vaccine trial tests an experimental vaccine composed of a small circular piece of DNA encoding the viral spike protein. The trial aims to assess the vaccine's safety and immune-stimulating effects in people, with results expected to inform future vaccine development.
The Imperial College London team, led by Dr. Danny Altmann, is developing new vaccines against anthrax and other bio-weapons using state-of-the-art technologies. The research will also contribute to a better understanding of emerging infectious diseases and the development of effective diagnostics and treatments.
A recent UK study published in The Lancet has found no association between the MMR vaccine and the development of autism or pervasive developmental disorders. Researchers analyzed data from over 1,300 cases and 4,469 controls, concluding that vaccination did not increase the risk of these conditions.
Researchers at UCI are working on a vaccine against melioidosis, caused by B. pseudomallei, a bacterium that thrives in water and can cause severe pneumonia and septic shock. The development of a safe and effective vaccine is crucial to blunt bioterrorism threats.
A phase 1 vaccine trial has demonstrated that a group A streptococcal vaccine appears safe and well-tolerated, inducing immune responses capable of conferring protection against multiple strains. The study's findings suggest that a specific dose and schedule may be effective in preventing group A streptococcal infections.
A novel protein vaccine candidate has demonstrated full protection against a lethal aerosol challenge with ricin toxin in mice, offering a promising solution to bioterrorism threats. The vaccine, RTA 1-33/44-198, was designed using molecular modeling and protein engineering techniques.
A new breed of vaccine-producing plants is being developed to combat global health issues, including cholera and diarrhea. The innovative technology uses minimal processing to yield heat-stable vaccines for oral delivery.
A new triple-vaccine strategy has been shown to stimulate a strong HIV-specific immune response in monkeys, demonstrating its potential as an improved method of protection against the virus. The approach uses a series of three vaccines that build on each other to generate a stronger immune response than might otherwise be possible.
Researchers have developed an intranasal SARS vaccine that protects African green monkeys from infection with a single dose, delivering the vaccine directly into the respiratory tract. The vaccine targets the SARS spike protein and induces neutralizing antibodies against the virus.
Researchers found thimerosal exposure in mice led to autism-like behaviors, including abnormal responses to environments and brain abnormalities. The study suggests a potential connection between genetic susceptibility and environmental triggers for autism, highlighting the need for further research and intervention strategies.